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Introduction {#sec1}
============

Induced pluripotent stem cells (iPSCs) have been recognized as an attractive cell source for stem cell therapy, drug discovery, and disease modeling ([@bib44], [@bib45], [@bib55]). Since blood cells can be easily obtained through a minimally invasive process and have been widely applied in clinical diagnosis, we and other investigators have been working on reprogramming of peripheral blood (PB) mononuclear cells (MNCs) in recent years ([@bib2], [@bib7], [@bib6], [@bib12], [@bib14], [@bib22], [@bib28], [@bib29], [@bib32], [@bib33], [@bib34], [@bib42], [@bib43], [@bib49], [@bib48]). More recently, we reported an efficient system for PB MNC reprogramming using an optimized combination of episomal vectors that express five reprogramming factors, and found that thousands of integration-free iPSC colonies can be generated from 1 × 10^6^ PB MNCs ([@bib49], [@bib48]). This seemingly simple but highly efficient system has been adopted by many other laboratories ([@bib6], [@bib21]). The episomal vectors we used are plasmids carrying EBNA1 and oriP, which maintain the transgene expression for 1--2 weeks, allowing for successful reprogramming, and are gradually depleted from the cells during passage leading to generation of integration-free iPSCs.

For clinical regenerative medicine applications, patient-specific iPSCs, which often carry a disease-causing gene(s), have to be genome edited before differentiation into functional cells for therapy. CRISPR-Cas9 is a powerful genome editing technology to achieve this goal ([@bib26], [@bib37], [@bib51]). CRISPR-Cas9 is an adoptive immune system evolved in bacteria and Archaea to fight against invading agents such as bacteriophages or plasmids ([@bib50]), and has been successfully engineered to target the human genome ([@bib18]). Diverse CRISPR systems have been adapted for use in editing iPSCs ([@bib18], [@bib39], [@bib57]), among which the most commonly used system is derived from *Streptococcus pyogenes*. In this system, single guide RNA (sgRNA) guides endonuclease Cas9 to cleave a double-stranded DNA sequence of ∼20 bp in length at 3 bp upstream of the protospacer adjacent motif (PAM) NGG. After double-stranded DNA cleavage, the damage is often repaired by error-prone non-homologous end joining (NHEJ) or precise homologous recombination (HR) pathway ([@bib17], [@bib52]). If a donor template that harbors both left and right homology arms is provided, the cells can be tricked to use the donor template to repair the damage instead of searching for the sister chromatids. As a result, a DNA fragment of interest can be precisely knocked in. However, this homology-directed repair (HDR)-mediated knockin system is far less efficient than gene knockout. In attempt to break this bottleneck in precise genome editing, we and other investigators developed a novel double-cut HDR donor, which is flanked by sgRNA recognition sequence and is released after CRISPR-Cas9 cleavage ([@bib23], [@bib58]). After optimization, we observed an ∼5-fold increase in HDR efficiency using the double-cut donor with homology arms of 300--600 bp in length relative to circular plasmid donors ([@bib58]). Shortly after publication of our discovery, a similar study also reported the unprecedented editing efficiency of homology-mediated end joining compared with HR and microhomology-mediated end joining ([@bib53]).

The conventional strategy of regenerative medicine is generation of iPSCs first followed by genome editing. However, this is a time-consuming and labor-intensive procedure that requires ∼3 months of cell culture and two clone selections ([@bib13], [@bib16], [@bib17], [@bib19], [@bib41], [@bib56], [@bib61]). To cut back on the time spent, one-step simultaneous reprogramming and CRISPR-Cas9 genome editing to generate gene-modified iPSCs from somatic cells has been proposed ([@bib20], [@bib46]). [@bib20] have reported generation of gene edited iPSCs from fibroblasts by nucleofection of episomal vectors expressing reprogramming factors and CRISPR-Cas9 vectors. They targeted a GFP reporter to the *DNMT3A* locus during reprogramming. They observed up to 5% GFP-positive edited cells in bulk cells, which is five times higher than that achieved by direct editing of iPSCs. These data provide the first evidence for the benefit of combining somatic cell reprogramming and genome editing in a single step. However, the use of fibroblasts from human skin biopsy is problematic because of the high mutation rate of skin cells after long-term exposure to UV light radiation and the invasive procedure used to procure the cells ([@bib1]). In contrast to fibroblasts, PB cells are a preferable cell source for reprogramming ([@bib60]). As such, we attempted to generate gene edited iPSCs from PB MNCs by simultaneously reprogramming and gene editing.

In this study, we designed double-cut donors for HDR knockin of fluorescent reporters ([@bib58]). The knockin efficiency can be precisely determined by fluorescence-activated cell sorting (FACS) analysis of fluorescence-positive cells. A simple combination of reprogramming vectors and genome editing plasmids led to a nearly 10% knockin efficiency. Further improvements, including combining Cas9 and KLF4 expression in one vector and addition of SV40LT, increased HDR efficiency to up to 40%. Thus, in this study, we have established an optimized reprogramming and CRISPR-Cas9 system to efficiently generate gene-modified integration-free iPSCs directly from PB.

Results {#sec2}
=======

Simultaneous Reprogramming and Gene Editing to Generate Genome Edited iPSCs from PB MNCs {#sec2.1}
----------------------------------------------------------------------------------------

To generate gene-modified iPSCs, we transfected episomal vectors that express Yamanaka factors (OCT4, SOX2, MYC, and KLF4), and BCL-XL into PB MNCs after being cultured in erythroid medium for 6 days ([@bib42], [@bib43], [@bib49]). We additionally used a Cas9 episomal vector ([Figure 1](#fig1){ref-type="fig"}A), an sgRNA expressing plasmid vector that targets the end of *PRDM14* ORF sequence, and a double-cut donor plasmid as previously described ([@bib58]). The double-cut donor we designed was a promoterless GFP HDR donor that is flanked with sgPRDM14 recognition sequences ([Figure 1](#fig1){ref-type="fig"}B). After precise genome editing, the endogenous PRDM14 transcriptional machinery will drive the expression of both PRDM14 and GFP, which are linked with a self-cleaving E2A sequence ([@bib11]). The length of both left and right homology arms is 600 bp, which is sufficient for high-level precise gene knockin ([@bib58]). After nucleofection, cells were cultured in optimized reprogramming conditions ([@bib48]). Two weeks later, multiple iPSC-like colonies were observed. After four passages in culture, we analyzed the percentage of GFP-positive cells by flow cytometry ([Figure 1](#fig1){ref-type="fig"}C), which indicates the precise knockin efficiency at the *PRDM14* locus ([@bib58]). As a control, reprogramming factors (OS+B+M+K) only were used, which showed robust iPSC generation, but no knockin events were detected. After transfection of PB MNCs with both reprogramming factors and gene editing vectors (OS+B+M+K+Cas9+pD+sg), a 7%--8% knockin efficiency was observed in reprogrammed iPSCs ([Figure 1](#fig1){ref-type="fig"}D). In controls omitting Cas9 or sgPRDM14, no GFP-positive cells were detected (not shown), suggesting that the percentage of GFP-positive cells in experimental groups reflects HDR knockin efficiency.Figure 1Efficient Generation of Gene-Modified iPSCs by Simultaneous Reprogramming and CRIPSR Genome Editing(A) Schematic diagram of the episomal vector plasmids. SFFV is the spleen focus-forming virus U3 promoter. 2A (E2A) is a self-cleaving peptide derived from equine rhinitis A virus. Wpre, post-transcriptional regulatory element; SV40PolyA, polyadenylation signal from SV40 virus; OriP, EBV (Epstein-Barr virus) origin of replication; EBNA1, Epstein-Barr nuclear antigen 1.(B) Schematic of genome editing at the *PRDM14* locus. An sgPRDM14 was designed to create a double-strand break (DSB) at 4 bp after the stop codon TAG as previously described. The double-cut donor (pD) contains a left homology arm (HA), a 2A-GFP-Wpre-polyA cassette, and a right HA. This double-cut donor is flanked with the sgPRDM14 target sequence.(C) Schematic illustration of the overall experimental design.(D) Representative FACS diagrams of iPSCs at passage 4 (P4) after PB MNC reprogramming by nucleofection with indicated episomal vectors. OS, pEV-SFFV-OCT4-2A-SOX2; B, pEV-SFFV-BCL-XL; M, pEV-SFFV-MYC; K, pEV-SFFV-KLF4. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To prevent artifacts associated with a certain genomic locus, we further assessed our system in two additional gene loci: *AAVS1* and *CTNNB1*. *AAVS1* locus was suggested as a safe harbor site that could be potentially targeted in gene therapy ([@bib30]). *CTNNB1* encodes beta-catenin, a key protein in canonical WNT pathway that is expressed in iPSCs ([@bib24], [@bib31]). We designed sgRNAs targeting *AAVS1* or *CTNNB1* loci as well as the related two double-cut donors with 600 bp homology arms ([Figures S1](#mmc1){ref-type="supplementary-material"}A, S1B, S1D, and S1E). Similarly, we transfected PB MNCs and assessed knockin efficiency after four passages. FACS analysis showed a knockin efficiency of 8%--10% in these two sites ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1F). In controls without genome editing vectors, no GFP signal was detectable. In AAVS1 knockin donor vector, the EF1 promoter was used, which can drive the expression of GFP without integration. As such, we included controls that omit Cas9 or sgAAVS1. As expected, GFP was detectable shortly after transfection, but after reprogramming and four passages of culture, less than 0.01% cells were GFP^+^ (not shown), suggesting that almost all the GFP^+^ events in the experimental groups are due to precise insertion at the expected sites.

Taken together, we have achieved knockin efficiencies of up to 10% in three different loci after simultaneous reprogramming and gene editing. This efficiency is higher than a previous report (5%) ([@bib20]).

Increasing Knockin Efficiency of Reprogrammed iPSCs by Vector Optimization {#sec2.2}
--------------------------------------------------------------------------

Previously, we have reported that the use of one vector to express OCT4 and SOX2 (linked by a 2A self-cleaving peptide), and expressing MYC and KLF individually, can lead to high-efficiency reprogramming of PB MNCs, whereas other combinations considerably decrease the efficiency ([@bib49]). This finding indicates that a small change in vector design can have a big impact. In order to increase the knockin efficiency during reprogramming, we compared several vector combinations. We used one vector expressing both Cas9 and one Yamanaka factor by a 2A linker to replace two vectors expressing Cas9 and the reprogramming factor individually ([Figure 1](#fig1){ref-type="fig"}A). Since expression of OCT4 and SOX2 in one vector is critical to successful reprogramming, we constructed two episomal vectors: pEV-SFFV-Cas9-E2A-MYC (Cas9-2A-M or Cas9-M) and pEV-SFFV-Cas9-E2A-KLF4 (Cas9-2A-K or Cas9-K). When PB MNCs were nucleofected with Cas9-2A-M, together with other reprogramming and editing factors, we observed no iPSC-like colony formation even at 18 days after transfection. In comparison, a decent number of colonies could be obtained in combinations including Cas9-2A-K ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, knockin efficiency at *PRDM14* locus was 2- to 3-fold higher in the Cas9-2A-K group compared with the Cas9+K group (p \< 0.05) ([Figures 2](#fig2){ref-type="fig"}B and 2C). We further tested PB MNCs from a different donor, and observed the same level of increase in knockin efficiency with Cas9-2A-K versus Cas9+K ([Figure 2](#fig2){ref-type="fig"}D).Figure 2Increased Knockin Efficiency during PB MNC Reprogramming by Vector Optimization(A) Relative PB MNC reprogramming efficiency using indicated episomal vectors. Since the seeding cell number in each group may be different, the colony numbers from each group were calculated from seeding 1 × 10^6^ PB MNCs and normalized to the "OS+B+M+K" control group. Data shown are mean ± SEM from three independent experiments. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(B) Representative FACS diagrams of iPSCs at passage 4 (P4) after PB MNC reprogramming by nucleofection with indicated episomal vectors. Percentage of GFP^+^ cells represents knockin efficiency.(C and D) Knockin efficiency at *PRDM14* of iPSCs at P4 from two different blood donors. Data shown are mean ± SEM from three independent experiments. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Besides the *PRDM14* locus, we also tested the *AAVS1* and *CTNNB1* loci. Again, we observed ∼2-fold higher levels of knockin in the Cas9-2A-K group than the control Cas9+K group ([Figures S2](#mmc1){ref-type="supplementary-material"}). Collectively, our data demonstrate that using a single episomal vector to express Cas9 endonuclease and reprogramming factor KLF4 significantly increases gene editing efficiency of reprogrammed iPSCs.

SV40LT Further Increases Knockin Efficiency in Our Optimized Cas9-2A-K System {#sec2.3}
-----------------------------------------------------------------------------

We have shown enhanced knockin efficiency with the Cas9-2A-K system compared with the Cas9+K individual expression system. However, the reprogramming efficiency dramatically decreased in the Cas9-2A-K system. To rescue the defect of the new vector system in reprogramming, we screened a series of pluripotency factors in attempts to identify factors that can increase reprogramming efficiency but do not decrease knockin efficiency. We evaluated several factors with demonstrated positive effects on somatic cell reprogramming. Overexpression of the transcriptional regulator YAP1, one of the downstream effectors of the Hippo pathway ([@bib38]), has been reported to increase the efficiency of mouse iPSC generation ([@bib27]). NANOG is a well-known booster of somatic cell reprogramming ([@bib55]). LIN28A plays a positive role in reprogramming of fibroblasts from both humans and mice ([@bib55]). SV40LT considerably enhances blood cell reprogramming ([@bib7]). CDH1, also known as E-Cadherin, is critical for mouse embryonic stem cell pluripotency and can enhance reprogramming of mouse fibroblasts ([@bib5], [@bib40]). In addition, MIR302, a microRNA that is highly expressed in embryonic stem cells and has been reported to greatly promote reprogramming ([@bib35]). We cloned the aforementioned factors into our episomal vector carrying a strong SFFV promoter, and added them back individually in the Cas9-2A-K system, followed by assessing their effects on both reprogramming and gene editing. Reprogramming efficiency was determined by counting the number of alkaline phosphatase (AP)-positive colonies. AP is considered a universal pluripotency marker for all types of pluripotent stem cells, including iPSCs. We found that addition of YAP1, NANOG, or CDH1 did not show obvious changes in PB reprogramming efficiency in the Cas9-2A-K system, and MIR302 even slightly decreased reprogramming efficiency. Most surprisingly, and in contrast to previous reports on the positive effects of LIN28A in fibroblast reprogramming ([@bib55]), we found that LIN28A strongly inhibited PB MNC reprogramming in the Cas9-2A-K reprogramming and editing system ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). To further consolidate this conclusion, we added LIN28A in the PB reprogramming system without genome editing vectors (OS+B+M+K). Still, LIN28A decreased PB reprogramming by almost 100-fold (OS+B+M+K versus OS+B+M+K+LIN28A) ([Figure S3](#mmc1){ref-type="supplementary-material"}B). As for SV40LT, we observed increased reprogramming, but no statistical significance was achieved in some experiments ([Figures 3](#fig3){ref-type="fig"}A, S3D, and S3E).Figure 3SV40LT Increases Knockin Efficiency in Our Optimized System(A) Relative PB MNC reprogramming efficiency using indicated episomal vectors. The colony numbers from each group are normalized to the control group. Data shown are mean ± SEM from three independent experiments. ^∗^p \< 0.05; ^∗∗^p \< 0.01.(B) Knockin efficiency at *PRDM14* of iPSCs at P4 after reprogramming. Data shown are mean ± SEM from three independent experiments. ^∗^p \< 0.05.(C) SV40LT increases knockin efficiency at the *PRDM14* locus. Data shown are mean ± SEM from six independent experiments using three different blood cells donors. ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.(D) SV40LT increases knockin efficiency at the *AAVS1* locus. Data shown are mean ± SEM from four independent experiments using three different blood cells donors. ^∗^p \< 0.05.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Genome editing efficiency at the *PRDM14* locus was determined by flow cytometry after HDR knockin of the GFP reporter. We observed no obvious changes in editing efficiency when NANOG, YAP1, CDH1, or MIR302 was added in the control Cas9-2A-K group. However, inclusion of SV40LT almost doubled the knockin efficiency at the *PRDM14* locus ([Figures 3](#fig3){ref-type="fig"}B, 3C, and [S3](#mmc1){ref-type="supplementary-material"}C). To validate this finding, we tested the effects of SV40LT in editing another site, *AAVS1*. Again, we observed a 50% increase (∼20% knockin for without SV40LT versus ∼30% for with SV40LT) ([Figure 3](#fig3){ref-type="fig"}D).

Taken together, the optimized editing while reprogramming system with the use of both Cas9-2A-K and SV40LT led to an up to 4-fold increase in HDR genome editing efficiency ([Figures 3](#fig3){ref-type="fig"}C and 3D).

Characterization of Genome Edited iPSCs Generated with Optimized System from PB MNCs {#sec2.4}
------------------------------------------------------------------------------------

To determine whether genome editing during blood cell reprogramming affects the quality of iPSCs, we conducted single-cell cloning by FACS sorting GFP-positive cells at passage 2 after editing and reprogramming. iPSC colonies generated from the same blood samples but without CRISPR vectors were used as controls. After five passages, over 98% of *PRDM14* gene edited iPSCs were GFP positive (data not show). These cells showed typical morphology of human iPSCs and expressed pluripotency markers like NANOG and OCT4 ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A).

We next assessed whether knockin at the *PRDM14* locus is through HDR. PCR amplification of the target sequence of nine randomly selected PRDM14-GFP^+^ clones showed a predicted 2.6 kb band after HDR editing, which was absent in control unedited iPSCs ([Figure 4](#fig4){ref-type="fig"}B). Among these clones, 33% showed a single 2.6 kb band, indicating biallelic editing. Sequencing of the 2.6 kb bands showed that the cells were precisely edited by HDR ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In all the heterozygous clones, we observed indel mutations on the allele without knockin ([Figure S4](#mmc1){ref-type="supplementary-material"}C).Figure 4Characterization of Genome Edited iPSCs Generated with Optimized System(A) Morphology and confocal images of representative iPSC clones.(B) Determination of monoallelic versus biallelic HDR editing at *PRDM14*. Nine edited clones were analyzed.(C) PCR analysis of residual plasmids in iPSCs. Specific primers for plasmid backbone (BB) were used to amplify all the vectors. GAPDH serves as a DNA loading control. One copy of residual plasmid was mimicked by mixing of 1.6 pg of Cas9-2A-K plasmid with 1 μg of genomic DNA. Unedited iPSCs were generated with OS+B+M+K. Gene edited iPSCs were generated with "OS+B+M+Cas9-2A-K+pD-PRDM14+sgPRDM14+SV40LT".(D) H&E staining shows teratomas representative of three germ layers from gene edited iPSCs.(E) Digital karyotyping arrays of donor PB MNCs and generated iPSC lines. Unedited iPSCs were generated with OS+B+M+K. Gene edited iPSCs were generated with OS+B+M+Cas9-2A-K+pD-PRDM14+sgPRDM14+SV40LT. BAF, B allele frequency.(F) A summary of digital karyotyping as in (E). For Fisher\'s exact test, the p value was calculated by formula p = (a + b)! (c + d)! (a + c)! (b + d)!/\[a!b!c!d! (a + b + c + d)!\] = 0.55, in which a = 9, b = 10, c = 0, and d = 1. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

We further assessed the copy number of GFP in edited clones by qPCR. Seven out of nine clones show one or two copies ([Figure S4](#mmc1){ref-type="supplementary-material"}D), which is consisted with monoallelic or biallelic HDR knockin of GFP ([Figure 4](#fig4){ref-type="fig"}B). However, we found increased GFP copy number of 2.5 for one monoallelic HDR editing and of 3 for biallelic editing, suggestive of one random insertion of GFP fragment in each clone.

Our previous data showed that episomal vector plasmids are rapidly depleted from cells and thus integration-free iPSCs can be established ([@bib49]). Similarly, using specific primers targeting plasmid backbone, none or less than one copy of residual plasmids in gene edited iPSC colonies were detected after five passages ([Figure 4](#fig4){ref-type="fig"}C). These data suggest that transient expression of vectors for reprogramming and editing is sufficient for generation of integration-free gene edited iPSCs in a single step.

We then assessed genome integrity by digital karyotyping, which allows for identification of deletion or duplication of small piece of DNAs that would otherwise be invisible by conventional G-banding karyotyping analysis. To this purpose, nine iPSC colonies generated by episomal reprogramming without gene editing (OS+B+M+K) and 11 iPSC colonies generated by simultaneously reprogramming and gene editing (OS+B+M+Cas9-2A-K+pD+sg+SV40LT) were analyzed using Human Core Exome arrays ([@bib9]). All these iPSC colonies were derived from two donors. We did not detect any copy number variants (CNVs) in two PB MNC control samples and nine reprogrammed but not edited iPSC clones ([Figures 4](#fig4){ref-type="fig"}E, [S5](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"}). In addition, 10 out of 11 reprogrammed and edited iPSC clones also showed normal karyotyping, while we identified an alteration on chromosome 5 in one gene edited iPSC clone (clone E8; [Figure S5](#mmc1){ref-type="supplementary-material"}). Although these results invoke caution, there was no statistical difference in karyotypic abnormalities between edited and unedited iPSCs (Fisher\'s exact test; p = 0.55.) ([Figure 4](#fig4){ref-type="fig"}F).

We also examined the pluripotency by teratoma assay. Representative clones of edited and unedited iPSCs (three edited clones and two unedited clones) were injected into NOD/SCID immunodeficient mice. Two to 3 months later, teratomas were dissected for histological analysis. Both types of iPSCs were differentiated into cells representative of three germ layers, indicating that genome editing does not affect the iPSC pluripotency ([Figure 4](#fig4){ref-type="fig"}D).

Collectively, we conclude that integration-free iPSCs generated by simultaneous reprogramming and gene editing are indistinguishable from reprogrammed but unedited cells in morphology, phenotype, karyotype, and pluripotency.

Analysis of On-Target Cleavage and Off-Target Effects by High-Throughput Sequencing {#sec2.5}
-----------------------------------------------------------------------------------

Finally, we evaluated on-target cleavage and off-target effects in reprogrammed and edited cells. We analyzed iPSCs generated (1) without SV40LT; (2) with episomal pEV-SV40LT; and (3) with pSFFV-SV40LT, a regular SV40LT expressing plasmid vector. We compared pEV with regular plasmid to determine whether regular plasmid leads to rapid depletion of SV40LT vector. To our surprise, we found no significant difference in dynamics of vector depletion between pEV-SV40LT and pSFFV-SV40LT by qPCR ([Figure S4](#mmc1){ref-type="supplementary-material"}E). We then analyzed PCR products of on-target and off-target sites by Illumina sequencing. We observed high levels of indel mutations (from 65% to 91%) in all edited iPSCs ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, and [S1](#mmc1){ref-type="supplementary-material"}). Of interest, we found the inclusion of SV40LT tended to increase on-target cleavage relative to control (81% for pEV versus 88% for plasmid versus 67% for no SV40LT) ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}). In four out of six edited iPSC samples, absolutely no off-target effects were detected. Of interest, in two samples treated with pEV-SV40LT, we detected low levels (0.15% and 0.08%) of indel cleavage in 1 out 15 putative off-target sites (PRDM14-off12). Taken together, we detected high-level on-target and very-low-level off-target cleavage in our system.Table 1Detailed Information of Indels Induced at On-Target SitesIndel (bp)Reads (%)**Donor 1 with No SV40LT (total reads = 52,124)**TGAAGACTACTAGCCCT\|GCCAGG034.73TGAAGACTACTAGCCCT[t]{.ul}GCCAGG+142.21TGAAGACTACTAGC\-\-\-\--CAGG−57.17TGAAGACTACTAGCCCT[ct]{.ul}GCCAG+21.52TGAAGACTACTAGC-CTGCCAGG−11.49TGAAGACTACTAGCCCT[cct]{.ul}GCC+30.83TGAAGACTACTA\-\-\-\-\-\-\-\-\-\--−240.55TGAA\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--−250.54TGAAGACTACTAGCCC[c]{.ul}TGCCAGG+10.51**Donor 1 with pEV-SV40LT (total reads = 27,253)**TGAAGACTACTAGCCCT\|GCCAGG018.78TGAAGACTACTAGCCCT[t]{.ul}GCCAGG+145.84TGAAGACTACTA\-\-\-\--GCCAGG−58.79TGAAGACTACTAGCC-TGCCAGG−11.83TGAAGACTACTAGCCCT[ct]{.ul}GCCAG+21.40TGAAGACTACTAGC\--TGCCAGG−21.16TGAAGACTACTA\-\-\-\-\-\-\-\-\--G−100.94TGAAGACTACTAGCCCT[cct]{.ul}GCCA+30.81TGAAGACTACTAGC\-\-\--CCAGG−40.78TGAAGACTACTAGCCC-GCCAGG−10.70TGAAGACTACTA\-\-\-\-\-\-\-\--GG−90.65TGAAGACTACT\-\-\-\-\--GCCAGG−60.64TGAAGACTACTAGCC\-\-\-\-\-\-\--−100.56TGAAGACTACTAGCC\-\-\-\-\-\-\--−240.52**Donor 1 with pSFFV-SV40LT (total reads = 96,422)**TGAAGACTACTAGCCCT\|GCCAGG015.80TGAAGACTACTAGCCCT[t]{.ul}GCCAGG+148.50TGAAGACTACTAGCC\-\-\-\--AGG−511.64TGAAGACTACTAGCCTGCC-AGG−11.88TGAAGACTACTAGCCCT[ct]{.ul}GCCAG+21.60TGAAGACTACTAG\-\-\-\-\-\-\-\-\--−101.10TGAAGACTACTAGCCC-GCCAGG−11.05TGAAGACTACTAGC\--TGCCAGG−21.04TGAAGACTACTAGCCCT[cct]{.ul}GCCA+30.96TGAAGACTACTAG\-\-\-\-\-\-\-\--G−90.93TGAAGACT\-\-\-\-\-\-\-\-\-\-\-\-\-\--−250.86TGAAGACTACTAGCCC\-\-\--AGG−40.60TGAAGACTACTAG\-\-\-\-\-\-\-\-\--−240.59TGAAGACTAC\-\-\-\-\--TGCCAGG−60.58TGAAGACTA\-\-\-\-\-\--TGCCAGG−70.54TGA\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--−280.54TGAAGACTACTAGCCCT\-\-\-\-\--−80.50[^1]Table 2Frequencies of Indels Induced at On-Target and Off-Target SitesAmplicon NamesgRNA SequenceDonor 1 No SV40LTDonor 1 pEV-SV40LTDonor 1 pSFFV-SV40LTDonor 2 No SV40LTDonor 2 pEV-SV40LTDonor 2 pSFFV-SV40LTPRDM14-OnGAAGACTACTAGCCCTGCCAGG65.27% (52124)81.22% (27253)84.2% (96422)69.76% (29570)81.6% (67887)90.94% (54961)PRDM14-Off1AATGACTAgCTAGCCCTGCCCGGND (274018)ND (62373)ND (212254)ND (59100)ND (51196)ND (97940)PRDM14-Off2GAGGCCTAC-AGCCCTGCCTGGND (623372)ND (219831)ND (681736)ND (144926)ND (272086)ND (326654)PRDM14-Off3CATGACTAC-AGCCCTGCCTGGND (517147)ND (153567)ND (499286)ND (114781)ND (135985)ND (226137)PRDM14-Off4GA-GCCTAGTAGCCCTGCCAGGND (237917)ND (55138)ND (190509)ND (53336)ND (57903)ND (79913)PRDM14-Off5CCAGACT-CTAGCCCTGCCTGGND (249580)ND (73936)ND (212231)ND (55696)ND (39869)ND (64505)PRDM14-Off6CA-GACTACAAGCCCTGCCAGGND (421130)ND (114951)ND (576702)ND (237009)ND (352201)ND (592115)PRDM14-Off7-AAGCCTACGAGCCCTGCCTGGND (118176)ND (32067)ND (86715)ND (21460)ND (19937)ND (39503)PRDM14-Off8GATGACTA-TAGCCCTGCCTGGND (1182307)ND (293821)ND (1057123)ND (331444)ND (481926)ND (826539)PRDM14-Off9GAAGGA-ACTAGCCCTGCCAGGND (462623)ND (124231)ND (425694)ND (111054)ND (141785)ND (218065)PRDM14-Off10GAtAGAATAATAGCCCTGCCTGGND (201885)ND (59918)ND (172790)ND (42014)ND (33211)ND (55286)PRDM14-Off11GAAGTTCTCCTAGCCCTGCCAGGND (7777)ND (3705)ND (9608)ND (1880)ND (1175)ND (1651)PRDM14-Off12-AAGACCACAAGCCCTGCCTGGND (1168826)0.15% (162553)ND (1173091)ND (307115)0.08% (450589)ND (741222)PRDM14-Off13GAACACAAC-AGCCCTGCCAGGND (998855)ND (294816)ND (838294)ND (295574)ND (414908)ND (735881)PRDM14-Off14GAGGACTAC-AGCCCTGCCAGGND (52104)ND (14858)ND (60649)ND (17841)ND (13982)ND (19550)PRDM14-Off15GATGCCTAC-AGCCCTGCCCGGND (339253)ND (75118)ND (345323)ND (67702)ND (38205)ND (69752)[^2]

Discussion {#sec3}
==========

Building upon our blood cell episomal reprogramming system and an efficient double-cut donor-mediated knockin strategy, here we have reported a simultaneous PB cell reprogramming and CRISPR-Cas9 gene editing method. Although this is not the first report on establishing gene edited iPSCs directly from somatic cells, our optimized vector system is ∼10 times more efficient than the previous report in generating gene edited iPSCs from somatic cells in one step ([@bib20]).

The use of our optimized vector system can lead to high-level reprogramming and precise genome editing in a single step. Although the reprogramming efficiency is reduced with Cas9-2A-K compared with our previously optimized combination of episomal vectors ([@bib49], [@bib48]), we can still routinely obtain ∼100 iPSC colonies from 1 mL of PB when using OS+B+M+Cas9-2A-K+pD+sg+SV40LT. High-level gene editing efficiency of 20%--40% is attributable to two improvements: (1) the expression of Cas9 and KLF4 in a single vector, and (2) the inclusion of SV40LT. We observed that expression of KLF4 and Cas9 in one vector leads to a striking decrease of reprogramming efficiency and a significant increase in editing efficiency. This can be explained by the unique vector design. On the one hand, the compound vector decreased KLF4 expression in transfected cells, thereby leading to low-level reprogramming. On the other hand, all the successfully reprogrammed cells expressed relatively high levels of Cas9, which has contributed to improved DNA cleavage and HDR editing. We anticipate that the combination of Cas9 and KLF4 in one vector may also improve genome editing efficiency in systems other than blood cell reprogramming.

Of interest, the combination of MYC and Cas9 in one vector failed to generate any iPSC clones, which is reminiscent of our previous report that expression of MYC and KLF4 driven by one promoter leads to a 100-fold decrease in reprogramming compared with expression of the two factors individually ([@bib49]). These data suggest that high-level MYC is critical for successful blood cell reprogramming. In support of this argument, recent reports have demonstrated that MYC controls human pluripotent stem cell fate decisions and pluripotency surveillance ([@bib8], [@bib10]).

To further increase reprogramming efficiency, we screened multiple factors that were reported to have positive effects on reprogramming in certain cell types. We show that YAP1, NANOG, MIR302, and CDH1 have no obvious positive effects on blood cell reprogramming. In contrast to the reported positive effect of LIN28A on fibroblast reprogramming, we found that it strikingly suppresses PB MNC reprogramming. It is likely that our highly efficient vector combination has saturated the blood cell reprogramming system; thereby it masked unpronounced effects of many other factors identified in less efficient systems.

Interestingly, SV40LT increases gene knockin efficiency in our optimized Cas9-2A-K system. The mechanism of SV40LT-mediated increase in HDR knockin is unclear and deserves further investigation. Our data show an increase of on-target cleavage efficiency from 60%--70% to ∼90% after addition of SV40LT, which may have led to an increase in knockin efficiency.

Although SV40LT has shown roles in tumorigenesis and chromosome instability ([@bib3], [@bib4]), we observed only one clone (1/11) that showed an alteration on chromosome 5, and no statistically significant differences in genome integrity between unedited versus edited iPSCs have been achieved. We speculate that transient expression of SV40LT during reprogramming may not be sufficient for transformation and inducing chromosome instability, but it still calls for caution.

A recent paper reported an up to 50% gene knockout efficiency while reprogramming ([@bib46]). Since NHEJ-mediated knockout is much more efficient than HDR-mediated knockin, efficient knockout and reprogramming in a single step can be also achieved using our approach by simply omitting the donor template. In support of this argument, we observed up to 90% indel mutations in the bulk population of *PRDM14* edited iPSCs. In our study we used a double-cut donor plasmid to guide HDR editing; we believe that our optimized system using Cas9-2A-K and SV40LT should also increase editing efficiency when ssODN (single-strand oligo donor) donors are used ([@bib54]).

We also addressed the off-target effects in our reprogramming/editing system. We only observed low-level (0.08%--0.15%) cleavage in 1 out of 15 predicted off-target sites when pEV-SV40LT was used. However, iPSCs generated with regular SV40LT expressing plasmid did not show any off-target effects, while SV40LT expressed by both vectors increased editing efficiency to the same level. These data suggest that, in the future, SV40LT plasmid instead of pEV-SV40LT may be used in simultaneous reprogramming/editing systems to enhance editing efficiency while minimizing off-target cleavage.

Generation of integration-free iPSCs can also be achieved using Sendai virus ([@bib15]) or RNA transfection ([@bib47]). Similarly, Cas9 RNA or protein together with modified sgRNA can replace Cas9-sgRNA expressing plasmids for genome editing, even with higher DNA cleavage efficiency ([@bib25]). However, our system, based on episomal vectors and plasmid vectors, is easy to use, widely applicable, and more affordable.

In summary, we have identified an optimized combination of episomal reprogramming vectors and CRISPR-Cas9 genome editing vectors to achieve simultaneous high-level HDR knockin and reprogramming of PB MNCs into iPSCs. The gene editing efficiency is up to 40%, which is 10 times higher than the previous report. This simple and affordable approach will not only increase research productivity but also minimize the accumulation of mutations by decreasing culture time from 3--4 months to 1--2 months.

Experimental Procedures {#sec4}
=======================

Episomal Vectors {#sec4.1}
----------------

The majority of episomal vectors used in this study have been reported earlier ([@bib42], [@bib43], [@bib49], [@bib48]). Briefly, plasmids MYC (M), KLF4 (K), and BCL-XL (B) were constructed by inserting the open reading frames of MYC, KLF4, and BCL-XL into the episomal vector backbone, respectively. Plasmid OCT4-2A-SOX2 (OS), Cas9-2A-Puro (Cas9), Cas9-2A-MYC (Cas9-2A-M), and Cas9-2A-KLF4 (Cas9-2A-K) were constructed by inserting the open reading frames of OCT4-2A-SOX2, Cas9-2A-Puro, Cas9-2A-MYC, and Cas9-2A-KLF4 into the episomal vector backbone, respectively. The 2A peptide from equine rhinitis A virus was used to link two genes as previously described ([@bib49], [@bib59]).

sgRNA Design {#sec4.2}
------------

sgRNAs were designed using the Web-based program CHOPCHOP (<https://chopchop.rc.fas.harvard.edu/>) ([@bib36]) to target areas in close proximity to the stop codons of human *CTNNB1* and human *PRDM14* genes and on intron 1 of human *PPP1R12C* gene (for *AAVS1*) ([@bib58]). We preferentially chose sgRNAs with a G at the 5′ end which initiates U6-promoter-mediated transcription. Three sgRNAs were used in this study: sgCTNNB1 (GCTGATTGCTGTCACCTGG), sgPRDM14 (GAAGACTACTAGCCCTGCC), and sgAAVS1 (GGGGCCACTAGGGACAGGAT).

Donor Plasmid Construction {#sec4.3}
--------------------------

To construct donor plasmids targeting the *PRDM14* stop codon, the left and right homology arms were amplified from human genomic DNA, with the stop codon being removed and in-frame linked with the 2A sequence; the insert 2A-GFP-Wpre-polyA was amplified from another vector in the laboratory. A sgPRDM14 target sequence together with the [PAM]{.ul} sequence (GGAAGACTACTAGCCCTGCC[AGG]{.ul}) was tagged to the regions flanking the upstream and downstream homology arm (HA) ([@bib58]).

PB MNCs {#sec4.4}
-------

Human PB was obtained from Tianjin Blood Center with approval of the local research ethics committee (approval number: KT2017005-EC-1). MNCs were obtained by standard density gradient centrifugation with Ficoll-Hypaque (1.077 g/mL) (G&E Healthcare; 17-1440-03) at room temperature and were cultured in erythroid medium for 6 days before nucleofection as previously described ([@bib42], [@bib43], [@bib49], [@bib48]).

Genome Editing and Reprogramming {#sec4.5}
--------------------------------

Vectors for genome editing and reprogramming were transferred to PB MNCs by nucleofection. Vectors were extracted using Endofree Plasmid Maxi Kit (Qiagen; 12362). We prepared indicated plasmids in a sterile Eppendorf tube, followed by heating the tube at 50°C for 5 min to prevent contamination. The dosage of each plasmid was: OS, 2 μg; B, 0.5 μg; M, 1 μg; K, 1 μg; Cas9, 3 μg; Cas9-2A-M, 4 μg; Cas9-2A-K, 4 μg; pD (PRDM14, CTNNB1, or AAVS1), 2 μg; sg (PRDM14, CTNNB1, or AAVS1), 1 μg; YAP1, 1 μg; NANOG, 1 μg; MIR302, 1 μg; LIN28A, 1 μg; SV40LT, 1 μg; CDH1, 1 μg. After cool-down to room temperature, 57 μL of nucleofection buffer and 13 μL of supplement were added (Lonza; VPA-1003). PB MNCs were harvested by centrifugation at 200 × *g* for 7 min, 2 × 10^6^ PB MNCs were nucleofected with indicated plasmids, and 1 × 10^5^ to 2 × 10^6^ cells were plated in each well of six-well plates with inactivated mouse embryonic fibroblast (MEF) feeder cells being seeded 1 day before nucleofection. We used the U-008 program following the manufacturer\'s protocol (Lonza; Nucleofector 2b). Culture medium was gradually switched to E8 medium as previously described ([@bib42], [@bib43], [@bib49], [@bib48]). From day 0--14, cells were cultured in hypoxia (3% O~2~). After day 14--18 post nucleofection, the bulk populations of iPSCs were ready for passage and FACS analysis.

Single-Cell Cloning {#sec4.6}
-------------------

iPSCs were dissociated using Accutase to prepare single-cell suspension, followed by single-cell sorting immediately into 96-well plates coated with Matrigel (BD; 354277). Single-cell sorting was conducted using a BD FACS Aria III with a 70 mm nozzle under sterile conditions. Each well contained 100 μL of E8 medium supplemented with ROCK inhibitor Y-27632 (10 μM). After sorting, cells were cultured at 37°C with 5% CO~2~. Colony formation was seen 7 days after sorting. The cells were refreshed with E8 medium every 2 to 3 days ([@bib58]).

On-Target and Off-Target Cleavage Analysis {#sec4.7}
------------------------------------------

Two weeks after nucleofection, ∼1,000 colonies from each group were harvested for analysis. We predicted top 15 putative off-target sites using a Web-based program (<https://crispr.bme.gatech.edu/>) and designed primers to amplify on-target sites and these putative off-target sites ([Table S2](#mmc1){ref-type="supplementary-material"}). The PCR cycling conditions were: 95°C for 4 min followed by 98°C for 5 s, 64°--68°C for 10 s, 72°C for 10 s, for 30 cycles. High-throughput sequencing of PCR products was performed by Novogene using Hiseq-PE (paired end) 150. Data were analyzed using the Web-based program Galaxy (<https://usegalaxy.org/>). For clarity, we presented indels with reads of \>0.5% of on-target cleavage.

Digital Karyotyping {#sec4.8}
-------------------

Genomic DNA samples from indicated iPSCs were hybridized to HumanCoreExome arrays (Illumina, 20005132), and stained and scanned using the Illumina HiScan system per standard protocol ([@bib9]). Several algorithms have been used to detect CNVs, among which Log R ratio (LRR) and B allele frequency (BAF) are the commonly used methods. Because LRR is the logged ratio of observed probe intensity to expected intensity, any deviations from zero in this metric indicate copy number changes, while BAF is the proportion of hybridized sample that carries the B allele as designated by the Infinium assay. Thus, a normal sample would have discrete BAFs of 0.0, 0.5, and 1.0 for each locus (representing AA, AB, and BB).

Statistics {#sec4.9}
----------

Data were analyzed by paired student\'s t test or Wilcoxon test whenever appropriate. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ns, not significant.
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[^1]: The underlining indicates insert mutations. See also [Table S1](#mmc1){ref-type="supplementary-material"}.

[^2]: ND, not detected. The numbers indicate total reads.
